



Hematology Debate 2017

Invitation

Program starts

19:00 on Wednesday 15 February 2017

Scientific Committee

Paolo Ghia, Italy

Jesús San Miguel, Spain

Faculty

Christian Buske, Germany

Michele Cavo, Italy

Steven Coutre, USA

Michel Delforge, Belgium

Meletios A Dimopoulos, Greece

Gianluca Gaidano, Italy

John Gribben, UK

Georg Hess, Germany

Ulrich Jäger, Austria

Georg Lenz, Germany

Program ends

14:00 on Friday 17 February 2017

Location

Sheraton

Rome, Italy

María-Victoria Mateos, Spain

Philippe Moreau, France

Carol Moreno, Spain

Paul Moss, UK

Simon Rule, UK

Pieter Sonneveld, The Netherlands

Stephan Stilgenbauer, Germany

Clemens Wendtner, Germany

Sonja Zweegman, The Netherlands

This program is designed for general hematologists who are treating patients with a range of hematological malignancies and will feature updates from the recent ASH congress.

An application has been made to the EACCME* for CME accreditation of this event



Hematology
Medical
Education

janssen  Oncology

PHARMACEUTICAL COMPANIES OF 

You are invited to participate in the **Hematology Debate** being held on Wednesday 15 – Friday 17 February 2017. The latest updates from the American Society of Hematology (ASH) 2016 meeting will be integrated into the program.

The **Hematology Debate** offers a mix of plenary sessions and interactive workshops, designed to provide you with scientific and clinical updates on topics relating to a range of hematological malignancies. The format will enable you to participate in discussions on topics of interest with experts in the field and international peers, and gives you the opportunity to personalize the program to your own specific requirements. The program has been designed to ensure all aspects will be relevant to your clinical practice.

Educational objective

After attending this meeting, delegates should be able to:

- Reflect on strategies for the practical management of patients with hematological malignancies.

Program

Wednesday 15 February 2017

19:00–19:30 Welcome and opening session

19:30–20:30 **Plenary session**

Focus on B-cell lymphomas: updates from ASH 2016

Educational objective:

- Discuss recent clinical data relating to treatment of B-cell lymphomas and its potential impact on daily clinical practice.

20:30 *Networking dinner*

Thursday 16 February 2017

09:00–09:30 **Opening plenary session for Day 2**

09:30–11:00 **Parallel workshop sessions: Focus on B-cell lymphomas**

Practical management of patients with mantle cell lymphoma (MCL)

Educational objective:

- Explain the practical management of patients with MCL in specific clinical situations.

Practical management of patients with diffuse large B-cell lymphoma (DLBCL)

Educational objective:

- Explain the practical management of patients with DLBCL in specific clinical situations.

Practical management of patients with follicular lymphoma

Educational objective:

- Explain the practical management of patients with follicular lymphoma in specific clinical situations.

Practical management of patients with Waldenström's macroglobulinemia

Educational objective:

- Explain the practical management of patients with Waldenström's macroglobulinemia in specific clinical situations.

11:00–11:30 *Coffee*

11:30–13:00 **Plenary session**

Management of patients with multiple myeloma in 2017: What are the implications of the ASH updates for our clinical practice?

Educational objective:

- Discuss recent clinical data relating to multiple myeloma (MM) and its potential impact on daily clinical practice.

13:00–14:00 *Lunch*

14:00–15:30 **Parallel workshop session**

Practical management of patients with previously untreated MM

Educational objective:

- Explain the practical management of patients with previously untreated MM in specific clinical situations.

15:30–16:00 *Coffee*

16:00–17:30 **Parallel workshop session**

Practical management of patients with relapsed/
refractory MM

Educational objective:

- Explain the practical management of patients with relapsed/refractory MM in specific clinical situations.

18:30–19:00 Drinks and canapés

19:00–20:00 **Plenary session**

A focus on first-line treatment options for chronic
lymphocytic leukemia (CLL): an update from ASH 2016

Educational objective:

- Discuss recent clinical data relating to treatment-naïve CLL and its potential impact on daily clinical practice.

20:00 *Networking dinner*

Friday 17 February 2017

09:00–09:30 **Opening plenary session for Day 3**

09:30–11:00 **Parallel workshop session**

Practical management of treatment-naïve CLL

Educational objective:

- Explain the practical management of patients with treatment-naïve CLL.

11:00–11:15 *Coffee*

11:15–12:00 **Plenary session**

Strategies for the management of patients with relapsed CLL

Educational objective:

- Discuss recent clinical data relating to relapsed/refractory CLL and its potential impact on daily clinical practice.

12:00–12:30 *Coffee*

12:30–14:00 **Parallel workshop session**

Practical management of patients with relapsed/refractory CLL

Educational objective:

- Explain the practical management of patients with relapsed/refractory CLL.

14:00 Summary and close, followed by lunch

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, Belgium

Janssen-Cilag S.p.A
Via Michelangelo Buonarroti 23
I-20093 Cologno Monzese (MI), Italy